REFERENCE
FDA Food and Drug Administration.FDA Notification to the Cystic Fibrosis Community on Kalydeco (ivacaftor). Internet Document: 29 Aug 2012. Available from: URL: http://www.fda.gov
Rights and permissions
About this article
Cite this article
The US FDA has notified the cystic fibrosis (CF) community about the possible risk of cataract development in children taking ivacaftor [Kalydeco].. React. Wkly. 1418, 3 (2012). https://doi.org/10.2165/00128415-201214180-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201214180-00010